Impact of a TAK-1 inhibitor as a single or as an add-on therapy to riociguat on the metabolic reprograming and pulmonary hypertension in the SUGEN5416/hypoxia rat model

Background: Despite increasing evidence suggesting that pulmonary arterial hypertension (PAH) is a complex disease involving vasoconstriction, thrombosis, inflammation, metabolic dysregulation and vascular proliferation, all the drugs approved for PAH mainly act as vasodilating agents. Since excessi...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Daniel Morales-Cano, Jose Luis Izquierdo-García, Bianca Barreira, Sergio Esquivel-Ruiz, Maria Callejo, Rachele Pandolfi, Palmira Villa-Valverde, Ignacio Rodríguez, Angel Cogolludo, Jesus Ruiz-Cabello, Francisco Perez-Vizcaino, Laura Moreno
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2023-03-01
Saila:	Frontiers in Pharmacology
Gaiak:	pulmonary hypertension antiproliferative metabolomics combination therapy right ventricle
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1021535/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!